Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21)

Post Date

August 5th 2013

Application Due Date

August 16th 2016

Funding Opportunity Number

PAR-13-311

CFDA Number(s)

93.865

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health
Income Security and Social Services

Eligibility Categories

State Governments
County Governments
City or Township Governments
Special District Governments
Independent School Districts
Public and State Controlled Institutions of Higher Education
Federally Recognized Native American Tribal Governments
Public Housing Authorities or Indian Housing Authorities
Non-Federally Recognized Native American Tribal Organizations
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Funding

• Award Range:

  $None - $200000

Grant Description

The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in pregnant women and the developing fetus. The overall goals of the FOA are to improve the safety and effectiveness of current drugs for pediatric or obstetric patients, and to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/pa-files/PAR-13-311.html